Securing funding for advanced therapeutic companies is increasingly challenging as these innovations often require substantial investment and long development timelines. As traditional funding models may fall short for cutting-edge therapies like gene editing, CAR-T, and mRNA platforms, it is essential to explore new financial strategies that meet the unique demands of this sector. This panel will examine the key funding challenges for advanced therapeutics and present:

• Key considerations for venture capital firms when identifying and measuring the value of investment opportunities in the advanced therapeutics industry
• Insights into venture philanthropy, milestone-based financing, and royalty-based investments as alternatives to traditional venture capital
• Considerations when weighing the pros and cons of government grants, public-private partnerships, and collaborations with large pharmaceutical companies to secure diverse funding streams
• Insights into securing grants and subsidies that offer financial support without equity dilution